XML 44 R35.htm IDEA: XBRL DOCUMENT
v3.26.1

Segment information - Significant Segment Expenses (Details) - USD ($) $ in Thousands | 3 Months Ended | 6 Months Ended
--- | --- | ---
Jun. 30, 2026 | Jun. 30, 2025 | Jun. 30, 2026 | Jun. 30, 2025
Indirect research and development expenses: |  |  |  |
Total research and development expenses | $ 3,923 | $ 7,953 | $ 7,516 | $ 16,243
Research and Development of Immunotherapies and Vaccines |  |  |  |
Direct research and development expenses: |  |  |  |
Total direct research and development expenses | 3,442 | 4,710 | 6,344 | 8,202
Change in direct research and development expenses | (1,268) |  | (1,858) |
Indirect research and development expenses: |  |  |  |
Total indirect research and development expenses | 481 | 3,243 | 1,172 | 8,041
Change In indirect research and development expenses | (2,762) |  | (6,869) |
Total research and development expenses | 3,923 | 7,953 | 7,516 | 16,243
Change in research and development expenses | (4,030) |  | (8,727) |
Research and Development of Immunotherapies and Vaccines | Personnel-related (including share-based compensation) |  |  |  |
Indirect research and development expenses: |  |  |  |
Total indirect research and development expenses | 440 | 2,450 | 979 | 6,394
Change In indirect research and development expenses | (2,010) |  | (5,415) |
Research and Development of Immunotherapies and Vaccines | Facility related |  |  |  |
Indirect research and development expenses: |  |  |  |
Total indirect research and development expenses | 15 | 350 | 102 | 685
Change In indirect research and development expenses | (335) |  | (583) |
Research and Development of Immunotherapies and Vaccines | Other indirect costs |  |  |  |
Indirect research and development expenses: |  |  |  |
Total indirect research and development expenses | 26 | 443 | 91 | 962
Change In indirect research and development expenses | (417) |  | (871) |
Research and Development of Immunotherapies and Vaccines | VTP-1000 Celiac |  |  |  |
Direct research and development expenses: |  |  |  |
Total direct research and development expenses | 2,936 | 1,782 | 4,358 | 2,764
Change in direct research and development expenses | 1,154 |  | 1,594 |
Research and Development of Immunotherapies and Vaccines | Barinthus legacy assets |  |  |  |
Direct research and development expenses: |  |  |  |
Total direct research and development expenses | 506 | $ 2,928 | 1,986 | $ 5,438
Change in direct research and development expenses | $ (2,422) |  | $ (3,452) |

X
- Definition Change In Direct Research And Development Expense, Current Period Compared To Prior Period + References No definition available. + Details
Name: | brns_ChangeInDirectResearchAndDevelopmentExpenseCurrentPeriodComparedToPriorPeriod
Namespace Prefix: | brns_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Change In Indirect Research And Development Expense, Current Period Compared To Prior Period + References No definition available. + Details
Name: | brns_ChangeInIndirectResearchAndDevelopmentExpenseCurrentPeriodComparedToPriorPeriod
Namespace Prefix: | brns_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Change In Research And Development Expense, Current Period Compared To Prior Period + References No definition available. + Details
Name: | brns_ChangeInResearchAndDevelopmentExpenseCurrentPeriodComparedToPriorPeriod
Namespace Prefix: | brns_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Direct Research And Development Expense + References No definition available. + Details
Name: | brns_DirectResearchAndDevelopmentExpense
Namespace Prefix: | brns_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Direct Research and Development Expenses + References No definition available. + Details
Name: | brns_DirectResearchAndDevelopmentExpensesAbstract
Namespace Prefix: | brns_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Indirect Research And Development Expense + References No definition available. + Details
Name: | brns_IndirectResearchAndDevelopmentExpense
Namespace Prefix: | brns_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Indirect Research and Development Expenses + References No definition available. + Details
Name: | brns_IndirectResearchAndDevelopmentExpensesAbstract
Namespace Prefix: | brns_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2 Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 220 -SubTopic 40 -Name Accounting Standards Codification -Section 55 -Paragraph 18 -Publisher FASB -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18 Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 220 -SubTopic 40 -Name Accounting Standards Codification -Section 55 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14 Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1 Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 912 -SubTopic 730 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1 + Details
Name: | us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=brns_ResearchAndDevelopmentOfImmunotherapiesAndVaccinesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | brns_ResearchAndDevelopmentTypeAxis=brns_PersonnelRelatedMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | brns_ResearchAndDevelopmentTypeAxis=brns_FacilityRelatedMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | brns_ResearchAndDevelopmentTypeAxis=brns_OtherIndirectCostsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=brns_VTP1000CeliacMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=brns_BarinthusLegacyAssetsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |